Extracellular Vesicles and Immune System in Ageing and Immune Diseases

Abstract

Immune system is essential for host homeostasis. Immune cells communicate with each other by binding to receptors or by releasing vesicles including chemokines and cytokines. Under healthy circumstances, immune cell-derived factors are critical for cellular growth, division and function, whereas under conditions such as ageing and inflammatory states, they can aggravate pathologies and cause disease. Cell-derived membranous extracellular vesicles mediate cell-to-cell communication and are implicated in various physiological and pathological processes involving ageing and age-related diseases. Extracellular vesicles are responsible for spreading detrimental factors to the surroundings and the propagation phase of inflammatory diseases. The regulation of extracellular vesicles is a putative target for treatment of inflammatory diseases. Moreover, their features are ideal for developing biomarkers and drug delivery systems modulated by bioengineering in inflammatory diseases. The present review summarizes the current understanding of extracellular vesicles in ageing and inflammatory diseases.

INTRODUCTION

The conserved immune defense system is essential for host homeostasis [1, 2] as it triggers innate and adaptive immunity. Both mechanisms protect the host against foreign invaders [3]. The triggered innate immune system can immediately recognize non-specific pathogens without immunological memory and rapidly lead to an inflammatory reaction [4]. Innate immune cells are recruited towards the infected and inflammatory areas to engulf foreign substances [5]. Macrophages, monocytes, neutrophils, dendritic cells and natural killer (NK) cells sense pathogen-associated molecular patterns (PAMPs) and damaged or dying cell-derived danger-associated molecular patterns (DAMPs) by their pattern recognition receptors (PRRs) such as cytoplasmic retinoic acid-induced gene (RIG)-I-like receptors (RLRs), absent in melanoma 2 (AIM2)-like receptors (ALRs), and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), as well as membrane-bound Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) [3, 6, 7]. Depending on the type of PRRs binding, activated immune cells initiate various intracellular signaling cascades to produce cytokines, chemokines, immune receptors and cell adhesion molecules, which are involved in the further recruitment of immune cells [4, 8]. Innate immunity is responsible for the induction of adaptive immunity [3]. The adaptive immune system is more specific and finely tuned to fight against non-self- and self-antigens [9]. The adaptive immune system is a delayed response, which generates immunological memory after an initial encounter with specific pathogens [8]. Primary contact with a specific antigen contributes to the transformation of immune cells such as naïve T and B cells into activated states. When the same pathogen re-enters organisms, memory T and B cells promptly respond depending on their memory [2, 10]. These cells implement antibody-mediated (humoral) or cell-mediated immune responses. B lymphocytes play an important role in producing immunoglobulin (Ig) antibodies that attach to and neutralize specific foreign pathogenic antigens. T lymphocytes such as cytotoxic T cells and helper T cells, are involved in cell-mediated immune responses [4]. With ageing, immune system shows chronic, sterile, and low-grade inflammation (inflammaging) and immunodeficiency (immunosenescence), and aberrant immune responses can lead to immune disorders and age-related diseases [11, 12].

Cell-derived membranous extracellular vesicles (EVs) mediate intercellular communication after their release into the extracellular environment [13, 14]. EVs can be classified as exosome, microvesicle, and apoptotic bodies depending on their intracellular origin, size (diameter 100 to 1,000 nm) or composition [13, 14]. EVs enclosed in phospholipid bilayer contain lipids, nucleic acids and proteins (e.g., cytokines, proteinases, adhesion molecules, signal transduction proteins and chemokines) that deliver signals to the cytosol of recipient cells and activate intracellular signaling pathway by their internalization or receptor-counter receptor interactions at plasma membrane [13-15]. EVs play important roles in the regulation of physiological and pathological processes including Alzheimer disease (AD), Parkinson disease (PD) and amyotrophic lateral sclerosis (ALS) [16]. In particular, EVs are involved in regulating the immune response, inflammation and tissue homeostasis [15]. In addition, acute insults may provoke pro-inflammatory EVs serving host defense. Under chronic inflammatory conditions, such as cellular senescence, EVs delivering immunosuppressive contents act in an attempt to prevent persistent inflammatory response, acting as a counterweight to inflammatory conditions [17, 18]. In response to the inducer, EVs evoke either pro-inflammatory or anti-inflammatory responses [19]. This review summarizes current knowledge about EVs in immune systems under ageing and inflammatory states and their potential for clinical applications.

OVERVIEW OF EXTRACELLULAR VESICLES

Exosomes (30~100 nm in diameter) are released by the endocytic pathway in various cell types and transport cell-type specific molecules [20, 21]. Late endosomes called multivesicular bodies (MVBs) or multivesicular endosomes (MVEs) containing internal intraluminal vesicles (ILVs) fuse with host plasma membrane to secrete ILVs into the extracellular environment (exosomes) [20, 21]. Otherwise, some late endosomes fuse with lysosomes to degrade cytoplasmic contents (Fig. 1) [22].

Fig. 1.

Schematic overview of the extracellular vesicles (EVs). EVs enclosed in phospholipid bilayer from secreting cells contain nucleic acids and proteins that deliver signals to the cytosol of recipient cells. EVs can be classified as exosome, microvesicle, and apoptotic bodies depending on their intracellular origin, composition and size.

Multiple intracellular steps are required to accomplish exosome biogenesis and release. Exosome biogenesis proceeds in endosomal sorting complexes required for transport (ESCRT) dependent or ESCRT independent manner. Sub-complexes of ESCRT comprise ESCRT-0 (Vps27, Hse1), ESCRT-I (TSG101, Vps28, Vps37, and Mvb23), ESCRT-II (Vps22, Vps25, and Vps36) and ESCRT-III (Vps20, SNF7, Vps24, Vps2, Vps60, and Vps46) [23, 24]. ESCRT-0 senses and recruits ubiquitinated cargo on endosomal membranes, and ESCRT-0 recruits ESCRT-1, which subsequently recruits ESCRT-II. Both ESCRT-I and -II are involved in membrane deformation and inward bud formation. Furthermore, ESCRT-1 recruits ESCRT-III via ESCRT-II, and ESCRT-III is implicated in scission to form ILVs [23, 25]. Without ESCRT complexes, tetraspanins (CD9, CD81, and CD63) and ceramide are associated with exosome biogenesis [26]. Tetraspanins organize membrane microdomains, called tetraspanin-enriched microdomains (TEM), with lipids and transmembrane proteins that include Ig-superfamily (IgSF) receptors and integrins. Tetraspanins are implicated in cargo sorting into ILVs [27]. The ESCRT complex and tetraspanins play roles in protein sorting into vesicles [28].

Exosomes contain enriched cholesterol, sphingolipids (SLs) and phosphatidylcholine (PC). Ceramide (Cer), a central unit of SLs, is product of sphingomyelin (SM) hydrolysis by neutral sphingomyelinase (nSMase); it promotes membrane budding, generates ILVs [29], and is involved in lipid sorting [29, 30]. Other sphingolipid metabolite, sphingosine 1-phosphate (S1P) is also associated with cargo sorting into ILVs by binding to S1P receptors on MVBs [31]. In particular, heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and Y-box protein 1 (YBX1) are involved in exosomal microRNA (miRNA) sorting [32, 33]. Major vault protein (MVP) participates in RNA and miRNA sorting into vesicles [34, 35].

MVBs then move toward the plasma membrane for secretion via microtubule and actin cytoskeleton [36], and the motor proteins (kinesins, dynein, and myosins) superfamilies are responsible for vesicular transport [37]. The Rab family of small guanosine-5’-triphosphates (GTPases) regulate intracellular vesicle trafficking and membrane fusion [early endosome (Rab4 and Rab5), recycling endosome (Rab11), late endosome (Rab7 and Rab9), and exosome secretion (Rab27)] [28, 38]. Rab27a and Rab27b are associated with MVB docking at the plasma membrane [39]. Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) might contribute to the docking process by assembling vesicular SNAREs (v-SNAREs) and target SNAREs (t-SNAREs). These trans-SNARE complexes are implicated in MVB fusion with the plasma membrane. Therefore, SNARE proteins are required for exosome release into the extracellular environment [40, 41]. Exosome secretion is also mediated by activation of the transcriptional factor, p53 [42].

Microvesicles are directly derived from the cell surface via outward bud formation and fission, and range from 50~1,000 nm in diameter [13]. Plasma membrane redistribution and contraction of the cytoskeletal structure contribute to microvesicle formation [43]. When cargo components move to the cellular periphery at sites of microvesicle shedding, changes in membrane-bending associated proteins and the plasma lipid composition change, and become involved in membrane rigidity and curvature, causing membrane budding [44]. Lipid raft microdomains are enriched in sphingolipids and cholesterol, and are important in the budding process [43, 45]. Acid SMase (aSMase) generates cone-shaped Cer, which alters microvesicle membrane curvature and fluidity [46, 47]. Cholesterol might be involved in microvesicle shedding [48, 49]. Modification of membrane asymmetry is ATP-dependently generated by aminophospholipid translocases such as flippases and floppases that move phospholipids from outer to inner leaflets and vice versa, respectively. Scramblases that are ATP-independent and Ca²⁺-dependent, are involved in the distribution of the plasma membrane, by non-specifically translocating phospholipids between outer and inner leaflets [50]. Phosphatidylserine (PS) is translocated to the outer leaflet for shedding and lipid rafts also play pivotal roles in PS exposure [51].

Membrane bending and budding processes are also regulated by contractile proteins that add contractile or tensile forces [43, 44]. Actin-myosin interaction induces fission to release microvesicles from the surface of parent cells. The small GTP-binding protein ADP-ribosylation factor 6 (ARF6) facilitates the phospholipase D (PLD)-extracellular signal-regulated kinase (ERK)- myosin light chain kinase (MLCK) signaling pathway, which activates myosin light chain (MLC) that subsequently promotes actomyosin contractility at the necks of forming vesicles, thus releasing microvesicles into the extracellular space [52].

Apoptotic bodies are vesicles that bleb from the plasma membranes of cells undergoing apoptosis [53]. Apoptotic cells can generate diverse apoptotic cell-derived EVs (ApoEVs) including membrane-bound vesicles (ApoBDs) and apoptotic microvesicles (ApoMVs) [54]. Apoptotic bodies allow phagocytes including macrophages and DCs to recognize and engulf apoptotic cells [53]. They can transport fragmented DNA and cytoplasmic organelles, as well as cytokines and miRNA; therefore, they play crucial roles in immune regulation during infection and autoimmunity [54, 55].

IMMUNE CELLS AND EXTRACELLULAR VESICLES IN IMMUNE SYSTEM

All types of immune cells such as macrophages, neutrophils, dendritic cells (DCs), T, and B lymphocytes secrete EVs, which are essential for cell-cell communication [56-60]. After recognition of foreign agents or stimuli, they release EVs with altered cargo [61]. Recent evidence indicates cytokines are encapsulated in EVs and then released into extracellular environment [19, 62]. These EVs include the cytokines [interleukin (IL)-1ra, IL-1β, IL-6, IL-8, and IL-10], chemokines [monocyte chemoattractant protein-1 (MCP-1) and regulated upon activation, normal T cell expressed and secreted (RANTES)], miRNA, and foreign constituents, which are important for the innate and adaptive immune systems [19, 63, 64]. Also, EVs provoke either pro-inflammatory or anti-inflammatory responses depending on the stimuli [19].

Macrophages are derived from the yolk sac, fetal livers or bone marrow and participate in phagocytosis, tissue remodeling, and homeostasis. They have the important ability to scan surrounding signals via their sensors such as TLRs, NLRs, CLRs, RLRs and ALRs [56, 65]. Activated macrophages release cytokines [IL-1β, IL-6, IL-12, IL-18, and IL-10], growth factors [transforming growth factor (TGF)-β] and chemokines [chemokine C-X-C motif ligand (CXCL)1, CXCL2, and CXCL10] [65, 66]. Macrophages-derived EVs regulate the phenotype and function of recipient cells and are implicated in infections, such as those caused by Mycobacterium tuberculosis and human immunodeficiency retrovirus (HIV). These EVs can also deliver mycobacterial or viral components [64].

Neutrophils are specific polymorphonuclear leukocyte (PMNs) that are involved in acute and chronic inflammation. Neutrophils are abundant in the circulation [67]. During inflammation due to host-derived and bacterial-derived stimulants, circulating neutrophils are captured by endothelial adhesion molecules and recruited neutrophils form neutrophil extracellular traps (NETs) [67, 68]. In particular, neutrophils store granules containing microbicidal or enzymatic substances that are secreted upon activation. Azurophilic granules carry myeloperoxidase (MPO), serine proteases including neutrophil elastase (NE) and cathepsin G (CG) [57, 68]. Neutrophils also produce the cytokines and chemokines, IL-1α, IL-1β, IL-12, tumor necrosis factor (TNF)-α, IL-8, granulocyte colony-stimulating factor (G-CSF), interferon-α, and interferon-β [57]. Neutrophil-derived EVs can modify the inflammatory response of target immune cells by modulating production of pro- or anti- inflammatory cytokines [69]. In addition, EVs from neutrophils exhibit protective effects against inflammatory arthritis by inducing anti-inflammatory responses [70].

DCs are antigen-presenting cells (APCs) that are important for the induction of innate immunity as well as involved in adaptive immunity [71]. DCs are implicated in regulation of NK and NK T cells. Also, DCs interact with T and B cells: These cells prime naïve T cells (especially CD4⁺ T helper (Th) cells), which are required for T cell-dependent activation of B cells activation [71]. Also, DCs can induce naïve and memory B cell activation and support differentiation activated naïve B cells to plasma cells [71]. Classical DCs (cDCs) have CD11b, CD11c, and CD13 on their surfaces and express TLR2, TLR4, TLR10, and NLR. Cytokines secreted by cDCs include IL-8, IL-10, IL-12, and TNF-α [58]. Plasmacytoid dendritic cells (pDCs) produce type 1 interferon (IFN) against foreign pathogens [72]. Plasmacytoid DCs express surface markers such as CD303 and CD45RA, sensors such as TLR7 and TLR9, and release IFN-α, IL-6, and TNF [58]. Microparticles from patients with systemic lupus erythematosus (SLE) induce the production of pro-inflammatory cytokines, such as TNF, IFN-α, and IFN-γ, by pDCs [73].

T lymphocytes originate from bone marrow, mature in the thymus for selection, then migrate to the periphery. Naïve T lymphocytes can continuously circulate between blood and secondary lymphoid organs such as spleen and lymph nodes though the lymphatic system, and proliferate and differentiate into various types of T lymphocytes such as effector and memory cells after encountering antigens or costimulatory molecules of DCs [74, 75]. The major types of T lymphocytes are CD4 expressing Th cells and CD8 expressing cytotoxic T (Tc) cells. The CD4⁺ T cells comprise T regulatory (Treg), T follicular helper (Tfh), Th1, Th2, Th9, Th17, and Th22 types. These cells produce the anti-inflammatory or pro-inflammatory cytokines: IFN-γ and TNF (Th1), IL-4 and IL-5 (Th2), IL-9 (Th9), IL-17, IL-21, and IL-22 (Th17), IL-22 (Th22), IL-10 and TGF-β (Treg), and IL-21 (Tfh) [59]. T helper cells support B cell maturation for the generation of antibodies and regulate cytotoxic T cell activation [59, 76]. Regulatory T cells are important for maintaining self-tolerance [75] and CD8⁺ T cells generate IFN-γ, TNF, and IL-2, and kill cells infected with viruses [77]. Upon T cell receptor (TCR) activation, T cells release EVs [78]. Furthermore, overactivated T cell-derived EVs contain Fas ligand (FasL) and Apo2 ligand (Apo2L), which are associated with the activation of cell death pathway [79].

Like T lymphocytes, B lymphocytes originate form bone marrow and express B cell receptors (BCR) that allows them to initiate activation after contact with antigens [80]. During T cell-dependent activation, B cells can become activated and differentiate into plasma and memory B cells with the help of T cells [80]. T cell-independent B cell activation results in production of B cell forming low-affinity antibodies in response to lipopolysaccharides (LPS) and glycolipids [81]. B lymphocytes are implicated in the productions of antibodies and cytokines. In particular, B regulatory (Breg) cells can release IL-10, which is responsible for supporting the differentiation of Treg cells, and the inhibition of Th1, Th17, and CD8⁺ T cells [60]. Moreover, B cell-derived EVs containing MHC class II complexes are secreted in response to the interaction with antigen-specific T cells and BCR crosslinking, which plays an important role in the immune response [82].

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE AND EXTRACELLULAR VESICLES IN AGEING

Cellular senescence is characterized as a stress response to extracellular or intracellular insults. This senescence system can induce a permanent state of cell-cycle arrest and prevent malignant transformation [83]. Senescent cells undergo phenotypic changes such as acquiring the senescence-associated secretory phenotype (SASP). The SASP consists of cytokines [IL-1, IL-6, and IL-8], chemokines [CXCL-1, 2, chemokine C-C motif ligand (CCL)-3, 8, 11, 13, and 20], proteases [matrix metalloproteinase (MMP)-1, MMP-3, and MMP-10], and growth factors [insulin-like growth factor (IGF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)] [12, 83]. Senescent cells are normally cleared by immune cells [84]. However, senescent cells accumulate in multiple tissues due to age-related immunosenescence [12]. Concomitantly, SASP contributes to inflammaging, promoting inflammation by spreading the senescence phenotype to surrounding cells, which can lead to tissue dysfunction and age-related disease progression [11, 12].

For instance, aged vascular smooth muscle cells express IL-6, CCL2, ICAM-1, and TLR4 compared to young [85]. Plasma TNF-α and IL-8 are increased in elderly humans [86]. The gene expression of IFN, IL-2, IL-1A, MMP-13, CXCL2, CXCL9, CXCL14, and CXCL20, which are closely associated with nuclear factor (NF)-kappa B activity, is elevated in aged human fibroblasts [87]. Monocytes from elderly persons produce increased amounts of IL-6, IL1-ra, and C-reactive protein (CRP), but not TNF-α and IL-1 compared with younger persons [88]. Circulating EVs from the cerebrospinal fluid (CSF) of aged rats have higher levels of CD63 level but not IL-1β level compared with young adult rats [89]. Notably, aged populations are vulnerable to pathological conditions [90-92]. Systemic inflammation induced by injected LPS results in upregulated IL-1β and IL-10 levels in the brain and plasma of aged mice compared with adult mice. Notably, LPS induces aged microglia-derived IL-1β, IL-10, and TLR2 [90]. Microarray analyses showed increased levels of complement component (C)3, C4, MHC class I and II, CD68, CD44, and CD83 in brains from aged mice compared with adult mice. Similarly, LPS induced higher IL-6 and IL-1β levels in aged, than adult mice [91], and IL-6 production is upregulated in aged splenocytes with or without LPS stimulation [92].

Senescent cells are generally metabolically active and enhance EV secretion [93]. Ageing can influence the concentration, size, and functions of circulating EVs throughout the body [94]. Also, miRNAs such as miR-21 and miR-223 are increased within the exosomes [18]. The senescence-associated increase in EVs might be mediated partially by p53 [42, 95]. Transcription factor p53 can modulate the cell-cycle, DNA repair, cellular senescence and ageing [96], and targets endosomal compartment genes such as tumor suppressor-activated pathway 6 (TSAP6) and charged multivesicular body protein 4C (CHMP4C), which are implicated in exosome production. Under stress, p53 activation contributes to changes in membrane and vesicle trafficking [97]. The membrane phospholipid composition also changes with age [98]. The activation of nSMase in the liver and of nSMase and ceramidase in the brain and kidney during ageing is prominent, suggesting increased ceramide and/or sphingosine production [99]. Brains from aged monkeys show age-dependent endocytic pathology, as Rab GTPases including Rab5, Rab7 and Rab11 are increased [100]. Taken together, senescent cells exhibit enhanced or suppressed immune activities with ageing, and have altered EVs biogenesis and secretion.

In addition, senescent cells inducing inflammation state can further increase the cancer incidence in the aged individuals [21]. Cancer cells can exploit EVs for EV-induced immunosuppressive environment in tumor tissues or areas, which prevents the recognition by immune cells and removal of cancer cells [18]. Also, EVs from stem/progenitor cells have crucial ability to repair damaged tissues and modulate ageing process [101].

EXTRACELLULAR VESICLES IN HUMAN DISEASES

Under inflammatory conditions such as autoimmune and infectious diseases, EVs can carry PAMPs, DAMPs, autoantigens, and cytokines that contribute to the pathogenesis of human diseases by suppressing or enhancing immune responses [102]. In acute injuries, immune cells are likely to secrete pro-inflammatory EVs. In chronic or inflammatory diseases, they seem to release pro- or anti- inflammatory EVs depending on the inducers [18]. Thus, EVs might be key mediators in inflammatory diseases.

Inflammatory bowel disease

Inflammatory bowel disease (IBD) is an autoimmune condition that is due to the failure of immune tolerance to self-antigens. It leads to the production of auto-antibodies and impaired host tissues or organs. Patients with IBD are vulnerable to developing diverse autoimmune diseases such as psoriasis, coeliac disease, and multiple sclerosis [103]. Symptoms of IBD are abdominal pain, diarrhoea, and fever [104], and it is characterized by a dysregulated immune system and a chronic inflammatory response to an abnormal enteric microbiota, and genetic/environmental factors in the gastrointestinal (GI) tract. The major types of IBD are Crohn’s disease and ulcerative colitis (UC). Crohn’s disease involves the ileum, colon, and entire intestine, and UC involves the rectum and colon [105, 106]. A link between IBD and EVs has been identified. Intestinal luminal EVs from patients with IBD contain high levels of TNF-α, IL-6 and IL-8 [107], and Th1 and Th17 cells are involved in the pathogenesis of IBD [108, 109]. Th1 cell-derived IFN-γ and Th17 cell-derived IL-17 are key players in lesions of Crohn’s disease, as IL-12 and IL-23 production by DC is elevated [108]. Biopsies of intestinal tissues from patients with Crohn’s disease and UC have shown that Th17 cells and Th17-related cytokines, such as IL-17 and IL-21, are upregulated [110]. Furthermore, the colon and ileum of patients with IBD express IL-8 and high levels of Th17 effector cytokines including IL-17A and IL-22 [111]. Many cytokines derived from immune cells are associated with IBD, indicating the importance of regulating these cytokines [112]. EVs derived from DC with a TGF-β1 modification inhibit Th17 and delay IBD [113].

Rheumatoid arthritis

RA is a chronic autoimmune disease that is characterized by the production of autoantibodies, persistent synovitis, and joint damage [114, 115]. Autoantibodies such as rheumatoid factors (RFs) and anti-citrullinated protein antibodies (ACPAs) are associated with the severe clinical symptoms of RA such as pain, stiffness, swelling, and joint damage [114]. Rheumatoid factors are IgG, IgM and IgA that sense epitopes in the Fc fragment of IgG [116], and ACPAs recognize citrullinated peptides/proteins [117]. Both RFs and ACPAs are predominantly expressed in synovial fluid and blood of patients with RA [118]. The synovial compartment is a major region of inflammatory process in RA, and synovial cells, such as fibroblast-like and macrophage-like synoviocytes, are involved in cytokine overproduction, as well as cartilage and bone destruction in joints [115]. Elevated numbers of EVs in joints and EVs in patients are likely to play key roles in pathogenesis of RA [119, 120]. Excessive cytokines and chemokines within synovial tissues are responsible for endothelial cell activation, and the infiltration and accumulation of immune cells including leukocyte and CD4⁺ T cells, thus worsening the inflammatory response [114, 121, 122]. Both TNF-α and IL-1 might induce leukocyte recruitment to inflamed areas [123, 124]. Infiltrated CD4⁺ T cells generate IL-2 and IFN-γ. T cells interact with DCs that express MHC class II or cytokines such as IFN-γ, TNF-α, and IL-17, and activate macrophages and monocytes [122]. Direct interaction between T cells and macrophage contributes to TNF-α production [125]. IL-17 can also trigger macrophages to produce TNF-α and IL-1β [126]. Conversely, monocytes/macrophages are sources of TNF-α, IL-6, and IL-12 [127, 128], and regulators of T cell differentiation; for example, IL-12 and IFN-γ regulate Th1, and IL-1β and IL-6 regulate Th17 cell differentiation [129, 130]. These Th1 and Th17 cells are pathogenic and abundant in joints of patients with RA [131, 132]. EVs from DCs expressing IL-10 are immunosuppressive effects [133] and those from DCs expressing the tryptophan catabolic enzyme, indoleamine 2,3-dioxygenase (IDO) inhibit T cell activation and activate Treg cells, thus manifesting immunosuppressive and anti-inflammatory effects [134].

Systemic lupus erythematosus

SLE is a heterogeneous and systemic autoimmune disease caused by genetic susceptibility, aberrant immune disturbance, and hormonal as well as environmental risk factors [135, 136]. The symptoms of SLE are rash, nephritis, serositis, and thrombocytopenia, and SLE is characterized by the production of autoantibodies, disrupted self-tolerance, and organ dysfunction [137, 138]. Usually, SLE influences the kidneys, skin, blood, and joints [135, 137]. Patients with lupus nephritis have shown high levels of autoantibodies including anti-double-stranded DNA (dsDNA) antibodies [139]. SLE is associated with single-nucleotide polymorphisms (SNPs) in immune-associated genes or T-cell function-associated genes [137, 138]. Furthermore, TLRs, IL-10, IL-17A and costimulatory molecule CTLA-4 (CD152) polymorphisms are associated with SLE susceptibility [140-142]. EVs in patients with SLE express higher levels of IL-6, TNF-α, IL-1β, and IFN-α, than healthy individuals [143]. Microparticles from SLE plasma contain elevated levels of cytokines including IL-6, TNF, and IFN-α, and costimulatory surface proteins including CD80, CD86, and CD40. In addition, patients with SLE have higher proportions of apoptotic microparticles compared with heathy persons [73]. Microparticles from patients express high levels of Ig and complement proteins, and low levels of cytoskeletal and organelle composition proteins [144]. T cells in SLE help B cells to produce high-affinity IgG autoantibodies through TCR and MHC binding and costimulatory interactions such as CD28-B7 and CD40-CD40 ligand, and activated T cells are involved in cytokine production [137]. Anti-dsDNA antibodies can penetrate cells, subsequently leading to DNA fragmentation and apoptosis. Also, such antibody internalization is responsible for the upregulation of inflammatory cytokines such as TNF-α, IL-6, and IL-1β [145].

Type 1 diabetes

Type 1 diabetes (T1D) is a metabolic disease that is characterized by hyperglyceamia and inadequate insulin production. It results from a loss of insulin-producing pancreatic β cells in the islets of Langerhans. Patients with T1D are dependent on exogenous insulin replacement, and are at risk of developing serious complications including neuropathy, retinopathy, and nephropathy [146]. Most patients develop immunological disturbances including autoantibodies or viral infections [147]. The pancreas of patients with T1D contains large populations of cytotoxic CD8⁺ T cells within islets, increased CD68⁺ macrophages, CD20⁺ B, and CD4⁺ T cells, and low levels of Forkhead box protein P3 (FOXP3) ⁺ Treg cells and NK cells are evident during insulitis [148]. Pancreatic tissues from T1D donors also contain islets with infiltrative CD8⁺ T cells, human leukocyte antigen (HLA) class I hyperexpression, and β cell destruction in insulitic lesions [149]. The secretion of IL-17 by CD4⁺ T cells in response to β cell autoantigens is involved in β cell death in D1M [150]. EVs released in human and rat pancreatic islets carry autoantigens such as insulin/proinsulin, GAD65, and IA-2, which are associated with a loss of self-tolerance and the development of T1D [151]. In diabetic mice, EVs from islet mesenchymal stem cell-like cells promote the production of IFN-γ and the activation of autoreactive T and B cells [152].

Human immunodeficiency virus infection

Individuals infected with the HIV are at risk of developing acquired immunodeficiency syndrome (AIDS). Antiretroviral therapy (ART) can suppress HIV replication by inhibiting the reverse transcription of viral RNA and prolong life. Nevertheless, HIV in patients treated with ART is often accompanied by non-AIDS comorbidities such as cardiovascular disease, neurological disease, and cancers [153]. Infection with HIV is characterized by persistent inflammation and immune dysfunction [154], and massive amounts of inflammatory mediators, such as cytokines and chemokines [155]. Infection with HIV also promotes the secretion of EVs from T cells, monocytes, macrophages, and dendritic cells [156]. Plasma from patient infected with HIV has EVs containing IL-1α, IL-2, IL-12p70, TNF-α, CXCL10, and CCL2 [157]. Infected patients have reduced numbers of CD4⁺ cells [153]. The HIV targets CD4⁺ T cells and coreceptors such as CCR5 and CXCR4 to penetrate cells [158], and CD4⁺ T cells expressing CCR5 gradually become depleted in the GI tract, a major site of CD4⁺ T cell, via destruction of lymph node [154]. EVs are involved in both the pathogenesis of, and antiviral responses against HIV [156]. HIV exploits intracellular vesicle trafficking for its egress. The ESCRT system (TSG101) is needed for HIV release by being recruited at sites of viral budding [159]. The most prevalent protein in HIV, Nef is implicated in the vesicular trafficking network by interacting with Rab11, elevated microvesicle exocytosis, and apoptosis in CD4⁺ T cells. Nef from HIV is secreted from infected cells via CD45⁺ microvesicles in plasma [160]. In contrast, EVs stimulate the immune system to inhibit HIV spreading. EVs from infected cells contain APOBEC3G, which edits the HIV genome and targets HIV virion infectivity protein (vif), thus conferring antiretroviral capacity on recipient cells [161]. IFN-α is thought to restrict HIV replication and infection of CD4⁺ T cells by eliciting the APOBEG3 family in dendritic cells [162]. Besides this, tripartite-motif-containing 5α (TRIM5α) and tetherin are factors that restrict HIV [163].

Mycobacterium tuberculosis infection

Tuberculosis is a contagious disease with a steadily declining global incidence, but drug resistance is increasing. Tuberculosis is caused by infection with the pathogenic bacterium, Mycobacterium tuberculosis, that usually invades hosts by inhalation into the alveoli, where causes the formation of granuloma and subsequent necrosis [164]. Alveolar macrophages, DCs and monocyte-derived macrophages are involved in the phagocytic process of M. tuberculosis [165], which inhibits phagosome maturation into phagolysosomes in infected macrophages [166]. The glycosylated protein of M. tuberculosis can impede DC-mediated Th1 and Th17 polarization and block the protective effects of the bacillus Calmette-Guérin (BCG) vaccine [167]. M. tuberculosis is involved in changes in the membrane composition of EVs, such as vimentin and heat shock protein (HSP) 90, via infected macrophages [168]. In addition, M. tuberculosis infection results in stimulation of CD4⁺ and CD8⁺ that express antigen-specific IL-2 and IFN-γ, which enhance the protective immune response of the host [169].

CLINICAL APPLICATIONS OF EXTRACELLULAR VESICLES

EVs mediate intercellular communication and are implicated in various physiological and pathological processes. For that reason, EVs are likely to play crucial roles in inflammatory diseases and ageing. Even though EVs involve cellular homeostasis, they contribute to the ageing or pathological environment of hosts, and propagate the disease by carrying host or pathogen-derived elements [170, 171]. EVs transport and transfer pro- or anti-inflammatory cytokines, chemokines, and other inflammatory mediators from infected or resident immune cells to recipient cells, indicating their immunomodulatory capacity [19]. Thus, EVs have promising potential as biomarkers [172]. Cellular senescence is responsible for changes in circulating EVs dependently upon ageing [94]. The characteristic of SASP and potential of EVs as ageing biomarkers have been suggested through the results of proteomic analysis and profiling [172]. Increasing evidence indicates that EVs could serve as biomarkers in human diseases including cancer, central nervous system (CNS), and inflammatory diseases [173-175]. Disease stage can be monitored by analyzing circulating EVs in body fluids [173]. Microvesicles and exosomes in the CSF of injured CNS system contain specific biomarkers [174]. Myeloid-derived EVs and their cytokine expression in the CSF of patients with autoimmune disease can reflect disease progression and are considered as disease markers [175]. Thus, accumulated evidence indicates that EVs could be useful biomarkers for diagnostic, prognostic, predictive, and therapeutic interventions (Fig. 2).

Fig. 2.

Extracellular vesicles (EVs) as potential biomarkers in immune system disorders. EVs could serve as biomarkers in inflammatory diseases. Disease stage can be monitored by analyzing circulating EVs in body fluids including plasma, CSF, urine, and serum.

EVs might be ideal for drug delivery from the viewpoint of pharmaceutical drug development and useful in bioengineering [176, 177]. Therapeutic substances loaded into EVs can be transferred to target cells regardless of distance [178, 179]. Thanks to their self-derived nature, customized EVs have low immunogenicity and toxicity, and do not invoke immune responses [178]. The nature and size of EVs mean that they can protect their cargo against phagocytic clearance [177]. Lipid bilayer EVs are very stable and enough to be maintained in the circulation [178, 180]. Moreover, EVs can penetrate the blood-brain barrier to the CNS [179, 181]. The key features of EVs are desirable for delivering therapeutic agents to combat targeted pathological factors and for designing clinical applications.

EXTRACELLULAR VESICLES IN NEURODEGENERATIVE DISEASES

In the CNS, EVs are secreted by multiple cells, including microglia, astrocyte, and neuron, and contribute to intercellular communication [16]. EVs are implicated in neurodegenerative diseases such as AD, PD, and Huntington disease (HD) [16]. EVs carry misfolded or aggregated proteins and, therefore, could be used as biomarkers [16]. In AD, amyloid β (Aβ) peptide is secreted via EVs, and brain tissues from AD patients show EV proteins accumulated in amyloid plaques [182]. EVs secreted by neuronal cells can bind soluble Aβ, and the CSF-derived EVs from AD patients lead to mitochondrial impairment and neuronal cell apoptosis [183, 184]. Furthermore, EVs containing extracellular α-synuclein were observed in the CSF of patients with PD, which correlated with the degree of cognitive impairment [185]. Mutant α-synuclein plays a major role in PD pathology [186]. Also, mutant huntingtin transported by EVs propagates the HD phenotype, thus influencing motor and cognitive dysfunctions and striatal neuronal cell loss in HD [187]. EVs from stem cells or engineered EVs exhibit neuroprotective properties, including the release of neurotrophic factors and the ability to reduce neuroregeneration [188]. These characteristics suggest that EVs could be used for treating neurodegenerative diseases as well as immune diseases [188].

CONCLUSION

Extracellular vesicles are important for cellular homeostasis and cell-cell communication by carrying membrane and cargo components. They transport cytokines, chemokines, autoantigens, and danger signals that play potential roles in processes ranging from initiation to the progression of human diseases. EVs are involved in the ageing process and spreading pathological or disease states, thus, their regulation might prevent or retard the ageing process and be novel targets for therapeutic intervention. EVs are also promising tools for clinical applications such as biomarkers and EV-based immunotherapy in immune diseases.